01—Abstract
Summary
Summary of the 10-Q filed July 31, 2025. Cited figures are marked; the original filing is the authoritative source.
Biogen Inc. reported total revenue of $2,645.5 milliona for the three months ended June 30, 2025, an increase of 7.3% compared to the same period in the prior year.
This growth was primarily driven by a significant increase in Alzheimer's collaboration revenue (LEQEMBI) and contract manufacturing, royalty, and other revenue. However, product revenue experienced a slight decline of 1.1%, largely due to ongoing competition for its Multiple Sclerosis (MS) portfolio, particularly from generic versions of TECFIDERA and a TYSABRI biosimilar. Net income attributable to Biogen Inc. rose to $634.8 millionb, or $4.33 per diluted share, up from $583.6 million, or $4.00 per diluted share, in the prior year's quarter.
This improvement was supported by the top-line growth and a substantial reduction in Research and Development (R&D) expenses, partially offset by higher cost of sales and selling, general, and administrative (SG&A) expenses. The company ended the period with a strong liquidity position, with cash and cash equivalents totaling $2.8 billionc.
02—Key points
Key Highlights
- Total revenue increased by 7.3% to $2,645.5 million for the three months ended June 30, 2025, compared to $2,464.9 million in the prior year.
- Product revenue, net, decreased slightly by 1.1% to $1,878.7 million, impacted by MS portfolio competition.
- Alzheimer's collaboration revenue (LEQEMBI) surged by 365.3% to $54.9 million, indicating strong uptake.
- Net income attributable to Biogen Inc. increased to $634.8 million ($4.33 per diluted share) from $583.6 million ($4.00 per diluted share) in the prior year.
- Research and Development (R&D) expenses decreased by 21.1% to $399.0 million, reflecting cost optimization and portfolio prioritization.
- Acquired IPR&D, upfront and milestone expense increased significantly to $46.6 million due to new collaboration payments.
- Cash and cash equivalents stood at $2.8 billion as of June 30, 2025, demonstrating a healthy liquidity position.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed July 31, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $2.65B$2.46B | +7.3% |
| Cost of Revenue | $605.00M$546.00M | +10.8% |
| Gross Profit | $2.04B$1.92B | +6.3% |
| SG&A Expenses | $583.80M$553.80M | +5.4% |
| Operating Expenses | $1.90B$1.77B | +7.7% |
| Interest Expense | $72.60M$61.30M | +18.4% |
| Net Income | $634.80M$583.60M | +8.8% |
| EPS (Basic) | $4.33$4.01 | +8.0% |
| EPS (Diluted) | $4.33$4.00 | +8.3% |
| Shares Outstanding (Basic) | 146.50M145.60M | +0.6% |
| Shares Outstanding (Diluted) | 146.70M145.90M | +0.5% |
05—Questions
Frequently Asked Questions
What was the primary driver of Biogen's revenue growth in the second quarter of 2025?
The primary driver of Biogen's revenue growth was a significant increase in Alzheimer's collaboration revenue from LEQEMBI, alongside strong performance in contract manufacturing, royalty, and other revenue streams. This offset a slight decline in product revenue.
Why did Biogen's product revenue decline despite overall revenue growth?
Biogen's product revenue declined by 1.1% primarily due to increased competition for its Multiple Sclerosis (MS) portfolio, specifically the impact of generic entrants for TECFIDERA and biosimilar competition for TYSABRI, particularly outside the U.S. While some products like VUMERITY and newer launches like SKYCLARYS and QALSODY showed growth, they couldn't fully offset the declines in established MS products.
What is the company's outlook for its Multiple Sclerosis (MS) business?
Biogen expects its MS revenue to continue declining in 2025 due to ongoing and accelerating competition from generics and biosimilars for many of its MS products in both the U.S. and international markets. This includes expected impacts from TECFIDERA generic competition in Europe and TYSABRI biosimilar competition.
How has the company's R&D spending changed and what is the reason for it?
R&D expense decreased by 21.1% to $399.0 million for the three months ended June 30, 2025. This reduction is attributed to ongoing cost-saving measures from portfolio prioritization and the 'Fit for Growth' program, as well as funding received from Royalty Pharma for the litifilimab program. However, R&D spend increased for certain clinical trials, particularly for litifilimab and felzartamab.
What is the company's financial position regarding cash and debt?
Biogen maintains a strong liquidity position with cash and cash equivalents totaling $2.8 billion as of June 30, 2025. The company also issued $1.75 billion in Senior Notes in May 2025 and used the proceeds to redeem its 4.050% Senior Notes due September 15, 2025. Total borrowings remain substantial but were slightly down compared to the prior year-end.
06—Continue